Semaglutide Activates the Orexin/Hypocretin and Basal Forebrain Cholinergic Systems and Increases Acetylcholine Levels in the Hippocampus of Young and Aged Rats
Semaglutide activates specific neuronal systems and increases acetylcholine in the rat hippocampus, suggesting a potential mechanism for cognitive effects.
Where it sits
this study against the rest of the semaglutide corpusSummary and findings
The study investigated the effects of semaglutide on specific neuronal populations in rats, focusing on the orexin/hypocretin and basal forebrain cholinergic systems. Acute administration of semaglutide activated these systems and increased acetylcholine levels in the hippocampus. The research aimed to explore potential therapeutic mechanisms of GLP-1 agonists in neurological disorders.
Abstract
GLP-1 agonist drug repurposing efforts may establish new clinical niches in managing psychiatric and neurological disorders. However, a comprehensive understanding of GLP-1 neurobiology and an appreciation of specific neural mechanisms by which GLP-1 agonists might provide therapeutic effects is limited and stands as a barrier to these efforts. When considering current preclinical research evaluating GLP-1 agonist central mechanisms, a considerable knowledge gap remains regarding which specific cellular populations and systems define potential therapeutic effects in the brain. In this research, we used cFos immunohistochemistry to identify specific neuronal populations that exhibited altered cellular activity following acute administration of semaglutide to rats. We found that the orexin/hypocretin and basal forebrain cholinergic systems are activated following acute semaglutide administration in male and female young adult rats (3-5 months). Informed by the results of our histological analysis, we next employed in vivo microdialysis to test our hypothesis that semaglutide would acutely increase acetylcholine release in the rodent hippocampus. Here, we report that semaglutide acutely increases acetylcholine efflux in the ventral hippocampus of conscious and freely moving rats regardless of biological sex in both young adult and aged rats (23-26 months). Given the relevance of hippocampal cholinergic neurotransmission in learning and memory, our research mechanistically connects GLP-1 agonists with established targets in cognitive decline and dementia.
Background
The study addresses the potential repurposing of GLP-1 agonists, like semaglutide, for managing psychiatric and neurological disorders. Current understanding of GLP-1 neurobiology is limited, particularly regarding the specific neural mechanisms involved. This research aims to fill the knowledge gap by identifying neuronal populations affected by semaglutide, which could inform therapeutic strategies for cognitive decline and dementia.
Methods
The study used cFos immunohistochemistry to identify neuronal populations activated by semaglutide in rats. Acute administration was performed on male and female young adult rats (3-5 months). In vivo microdialysis was then used to measure acetylcholine release in the hippocampus of both young adult and aged rats (23-26 months).
Results
Acute administration of semaglutide activated the orexin/hypocretin and basal forebrain cholinergic systems in rats. It also increased acetylcholine efflux in the ventral hippocampus, observed in both young adult and aged rats, regardless of sex. These findings suggest a potential mechanism by which GLP-1 agonists could impact cognitive functions.
Interpretation
The study provides mechanistic insights into how semaglutide might influence cognitive processes through activation of specific neuronal systems. While the findings are statistically significant, their clinical relevance remains uncertain due to the preclinical nature of the study. The results align with existing literature on the role of hippocampal cholinergic neurotransmission in learning and memory, but further research is needed to assess clinical applicability.
Key findings
- Orexin/hypocretin and basal forebrain cholinergic systems activated after semaglutide administration.
- Semaglutide acutely increased acetylcholine efflux in the ventral hippocampus.
- Effects observed in both young adult (3-5 months) and aged rats (23-26 months).
- Findings consistent across male and female rats.
Limitations
- Preclinical study in rats, not humans.
- Acute administration only, no long-term effects studied.
- Single-site study with potential for limited generalizability.